Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
2013 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of healthcare interventions in primary care and community settings
2017
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
2016
The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis
2013
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement
2015 Standout
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants
2016 Standout
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Glycemic Management of Type 2 Diabetes Mellitus
2012
Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study
2011
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Severe Hypoglycemia and Risks of Vascular Events and Death
2010 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
2014
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
2016
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
2017
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis
2015
Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker
2012
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
2013
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
2013
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Type 2 diabetes
2017 Standout
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
2015 Standout
A graphene-based electrochemical device with thermoresponsive microneedles for diabetes monitoring and therapy
2016 Standout
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
2017 Standout
Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>
2010
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients
2011
Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study
2015
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
2014
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
2016
Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes
2012
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
2017
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
2017
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
2019 Standout
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Prediabetes: a high-risk state for diabetes development
2012 Standout
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
2011
Gut microbiota in human metabolic health and disease
2020 Standout
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease
2016 StandoutNobel
The influence of sex on renal function decline in people with Type 2 diabetes
2014
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
2018
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
2011
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trial
2017
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
2016 Standout
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
2013 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Diabetic Cardiomyopathy
2018 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
2010
Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association
2016
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
2016
Guidelines for Adult Stroke Rehabilitation and Recovery
2016 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease
2016
Mechanisms of Diabetic Complications
2013 Standout
Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)
2014
Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association
2016 Standout
An Updated Definition of Stroke for the 21st Century
2013 Standout
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
2011
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
2015 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
2011
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Effect of Moderate-Intensity Exercise Versus Activities of Daily Living on 24-Hour Blood Glucose Homeostasis in Male Patients With Type 2 Diabetes
2013
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
2012 Standout
Non‐alcoholic fatty liver disease ( NAFLD ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes
2017
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Value of Primordial and Primary Prevention for Cardiovascular Disease
2011
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of F. Travert being referenced
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
2009
Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds
2011
Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects
2008
Contemporary model for cardiovascular risk prediction in people with type 2 diabetes
2011
Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
2016
Intensive glucose control and macrovascular outcomes in type 2 diabetes
2009